scholarly journals ASSESSMENT OF DEPRESSION AND ANXIETY IN NEUROLOGICAL DISORDER PATIENTS AND THEIR RELATIONSHIP WITH QUALITY OF LIFE

2021 ◽  
Vol 21 (2) ◽  
pp. 112-123
Author(s):  
Priscilla Das ◽  
Nyi Nyi Naing ◽  
Nadiah Wan-Arfah ◽  
KON Noorjan ◽  
Yee Cheng Kueh ◽  
...  

Objectives: To assess the association between major depressive disorder, anxiety disorders and the quality of life of neurological disorder (brain tumour/brain disorder) patients. Methods: This study was conducted at Kuala Lumpur Hospital, Malaysia, a tertiary referral centre hospital for neurological disorder patients. The cross-sectional study design was applied. The Mini-International Neuropsychiatric Interview and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire were used in the study. Results: A total of 100 neurological disorder patients were included in the study. The study found that the Major depressive disorder correlated with almost all domains of the quality of life, except the nausea and vomiting scores. Logistic regression showed that emotional functioning and pain were related to major depressive disorder. Different anxiety disorders also correlated with quality of life in specific domains. The leading anxiety disorders that associated mostly with quality of life scales were post traumatic stress disorder, panic disorder lifetime and current, panic disorder with agoraphobia, obsessive compulsive disorder, anxiety disorder and with agoraphobia current and social phobia current (p < 0.05). Conclusions: There is a significant relationship between psychiatric disorders and quality of life neurological disorder patients. Therefore treatment along with psychiatric intervention should be implemented to improve the overall curability of the neurological disorder patients.

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.


2013 ◽  
Vol 30 (7) ◽  
pp. 697-712 ◽  
Author(s):  
Claudio Mencacci ◽  
Eugenio Aguglia ◽  
Giovanni Biggio ◽  
Lodovico Cappellari ◽  
Guido Di Sciascio ◽  
...  

2016 ◽  
Vol 12 (3) ◽  
pp. 719-736
Author(s):  
Alexander Joseph Steiner ◽  
Stephanie Marie Wright ◽  
Taylor Kuhn ◽  
Waguih William IsHak

Sign in / Sign up

Export Citation Format

Share Document